Neurocrine posts record Q3 with EPS $3.29, revenue $1.1B, raises 2026 INGREZZA net sales guidance

 

Neurocrine posts record Q3 with EPS $3.29, revenue $1.1B, raises 2026 INGREZZA net sales guidance to $2.9–$2.925B

• Q3 2026 revenue $1.1B, up 41% YoY; net product sales exceeded $1.1B, growing over 40% across the portfolio.
• INGREZZA delivered $801 million sales, up 17% YoY; 2026 guidance raised from $2.825–$2.875B to $2.9–$2.925B.
• 2027 INGREZZA expected to see double-digit volume growth despite mid- to high-single-digit pricing headwinds.
• Cronescity reached $211 million sales, first quarter above $200 million; over 15% diagnosed classic CAH treated.
• Vicat XR posted $107 million sales, first quarter above $100 million, with growth moderating amid safety concerns.
• Q3 2026 non-GAAP EPS $3.29, up 61% YoY; profitability record though gross and operating margin percentages were not disclosed.
• Company generated $400 million operating cash flow, ended quarter with roughly $800 million cash, repurchased $100 million shares.
• Key 2027 catalysts include Phase III readouts for osavapator in depression and directing in schizophrenia.
• Pipeline expanded with Phase II M1 muscarinic in Alzheimer’s cognition, obesity and gene therapy programs progressing.
• Q&A centered on INGREZZA durability, Vicat XR safety and trajectory, and muscarinic franchise competitive positioning.
• Main concern: Vicat XR post-marketing safety perceptions and potential regulatory scrutiny could slow adoption.
• Strong quarter, driven by INGREZZA outperformance, diversified product growth, and expanding operating leverage.

https://finviz.com/stock?t=NBIX&p=d